GSK answers critics with $2bn deal to become world-leader in cancer therapy

Retrieved on: 2021-06-14 11:15:00

Tags for this article:

Click the tags to see associated articles and topics

GSK answers critics with $2bn deal to become world-leader in cancer therapy. View article details on hiswai:

Excerpt

... and market a monoclonal antibody which targets part of the immune system — known as a checkpoint CD226 — to help the body fight tumours.

Article found on: uk.news.yahoo.com